@article{10.37349/etat.2024.00216,
abstract = {Adaptor proteins play essential roles in various intracellular signaling pathways. Signal-transducing adaptor protein-2 (STAP-2) is an adaptor protein that possesses pleckstrin homology (PH) and Src homology 2 (SH2) domains, as well as a YXXQ signal transducer and activator of transcription 3 (STAT3)-binding motif in its C-terminal region. STAP-2 is also a substrate of breast tumor kinase (BRK). STAP-2/BRK expression is deregulated in breast cancers and enhances STAT3-dependent cell proliferation. In prostate cancer cells, STAP-2 interacts with and stabilizes epidermal growth factor receptor (EGFR) after stimulation, resulting in the upregulation of EGFR signaling, which contributes to cancer-cell proliferation and tumor progression. Therefore, inhibition of the interaction between STAP-2 and BRK/EGFR may be a possible therapeutic strategy for these cancers. For this purpose, peptides that interfere with STAP-2/BRK/EGFR binding may have great potential. Indeed, the identified peptide inhibitor successfully suppressed the STAP-2/EGFR protein interaction, EGFR stabilization, and cancer-cell growth. Furthermore, the peptide inhibitor suppressed tumor formation in human prostate- and lung-cancer cell lines in a murine xenograft model. This review focuses on the inhibitory peptide as a promising candidate for the treatment of prostate and lung cancers.},
author = {Maemoto, Taiga and Sasaki, Yuto and Okuyama, Fumiya and Kitai, Yuichi and Oritani, Kenji and Matsuda, Tadashi},
doi = {10.37349/etat.2024.00216},
journal = {Exploration of Targeted Anti-tumor Therapy},
pages = {251--259},
title = {{Potential of targeting signal-transducing adaptor protein-2 in cancer therapeutic applications}},
url = {https://www.explorationpub.com/Journals/etat/Article/1002216},
volume = {5},
year = {2024},
number = {2}
}